ProPhase Labs PRPH 深 沪
交易中 11-04 11:00:47 美东时间
0.2988
-0.026
-8.09%
华盛通- 最 高0.323
- 今 开0.323
- 成交量 111.76万股
- 最 低 0.29
- 昨 收 0.3251
- 总市值 1241.25万
- 52周最高 0.9349
- 市盈率 静 --
- 换手率 2.69%
- 52周最低 0.2179
- 委 比 -66.67%
- 总股本 4154.12万
- 历史最高 15.25
- 量 比 5.43
- 振 幅 10.15%
- 历史最低 -1.87
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology
ProPhase Labs' BE-Smart, an 8-protein proteomic assay developed using mass spectrometry, has demonstrated 100% sensitivity for identifying Barrett’s Esophagus patients who progress to esophageal adenocarcinoma. Published in Clinical and Translational Gastroenterology, the study highlights its strong predictive power, including an AUC of 1.0 for patients progressing within three years, and the ability to stratify risk with minimal tissue. The test...
10-29 12:30
ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts
ProPhase Labs Inc. of New York has engaged RedChip Companies to manage its investor relations, as the biotech firm prepares to launch its BE-Smart™ esophageal cancer diagnostic, expand its Nebula Genomics platform, and pursue a $50 million accounts receivable recovery initiative. ProPhase CEO Ted Karkus believes the partnership will enhance visibility in the investment community, while RedChip CEO Dave Gentry highlighted ProPhase's promising grow...
10-28 12:00
ProPhase Labs to Present at the 2025 ThinkEquity Conference
ProPhase Labs Inc. (NASDAQ: PRPH), a biotech, genomics, and consumer products company, announced its participation in the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York. CEO Ted Karkus will present at 11AM ET, with live streaming available. Interested investors can register for one-on-one meetings or watch the presentation via the provided links. ProPhase Labs focuses on advancing healthcare through innovat...
10-24 12:00
ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Test Accepted by Journal of Clinical Gastroenterology and Hepatology
ProPhase Labs Inc. announced the acceptance of its pivotal clinical study validating the BE-Smart esophageal cancer test for publication in a leading gastroenterology journal, marking a significant milestone toward commercialization. Targeting a market of $7–$14 billion, BE-Smart offers a non-invasive, highly sensitive solution to assess Barrett’s Esophagus progression risk. The study demonstrated perfect sensitivity and high accuracy in predicti...
10-22 11:30
ProPhase Labs Signs Sales Agreement with WestPark Capital
Prophase Labs ( ($PRPH) ) has provided an update. On October 9, 2025, ProPhase ...
10-16 02:49
PROPHASE LABS, INC. ANNOUNCES COMPLETION OF IMPORTANT NEXT STEP FOR CROWN MEDICAL COLLECTIONS $50 MILLION A/R INITIATIVE
ProPhase Labs, Inc. announced that its three COVID-19 testing laboratory subsidiaries filed for Chapter 11 bankruptcy reorganization in New Jersey, seeking to recover tens of millions of dollars owed by insurance companies. This action aims to streamline collections and restore financial stability, with potential net collections of $50 million or more. The parent company and its other initiatives, including the development of a life-saving esopha...
09-23 12:00
ProPhase Continues its Exploration of a Crypto Treasury Strategy
ProPhase Labs announced an agreement for potential advisory services and is exploring investment opportunities in digital assets, specifically a crypto treasury strategy to enhance shareholder value. CEO Ted Karkus emphasized the company's underlying value, canceling its ELOC due to no interest in discounted financing. ProPhase aims to update shareholders on its Crown Medical Collections initiative, potentially generating $50 million, and progres...
09-22 12:00
ProPhase Labs Shareholders Approve Strategic Expansion, Including Increase In Authorized Shares To 1B
ProPhase Labs Stockholders Deliver Strong Mandate at Special MeetingUNIONDALE, NY, Sept. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next generation biotech, genomics
09-12 20:12
ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In Favor
ProPhase Labs shareholders overwhelmingly approved all proposals at the September 9 special meeting, with over 75% support for each item. This included authorization to increase the company's authorized shares to 1 billion, enabling strategic initiatives like a potential crypto treasury strategy and growth of its subsidiaries. The meeting follows the re-election of the board in June with over 90% support. CEO Ted Karkus emphasized the mandate all...
09-12 12:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers iSpecimen (NASDAQ:ISPC) shares increased by 80.7% to $1.35 during Tues...
09-10 01:06
